NASDAQ: BLRXBiolinerx Ltd Stock
$2.88+0.13 (+4.73%)
Updated Apr 17, 2025
BLRX Price
$2.88
Fair Value Price
N/A
Market Cap
$12.86M
52 Week Low
$2.30
52 Week High
$35.60
P/E
-288x
P/B
0.96x
P/S
0.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$28.94M
Earnings
-$9.22M
Gross Margin
68%
Operating Margin
-0.35%
Profit Margin
-31.9%
Debt to Equity
1.89
Operating Cash Flow
-$44M
Beta
0.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BLRX Overview
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLRX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BLRX
Ranked#426 of 463
Ranked#426 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important BLRX news, forecast changes, insider trades & much more!
BLRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLRX is good value based on its book value relative to its share price (0.96x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
BLRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BLRX due diligence checks available for Premium users.
Valuation
BLRX fair value
Fair Value of BLRX stock based on Discounted Cash Flow (DCF)
Price
$2.88
Fair Value
$0.03
Overvalued by
10,932.87%
BLRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BLRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-288x
Industry
-177.72x
Market
27.98x
BLRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.96x
Industry
4.05x
BLRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLRX's financial health
Profit margin
Revenue
$11.7M
Net Income
-$3.2M
Profit Margin
-27.1%
BLRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BLRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.9M
Liabilities
$25.4M
Debt to equity
1.89
BLRX's short-term assets ($27.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLRX's short-term assets ($27.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLRX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BLRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.6M
Investing
$11.2M
Financing
-$1.1M
BLRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLRX vs Biotech Stocks
Biolinerx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.